B. Skikne

发表

Iron deficiency: definition and diagnosis

J. Cook, B. Skikne, 1989, Journal of internal medicine.

Localization of bone morphogenetic proteins (BMPs)-2, -4, and -6 within megakaryocytes and platelets.

B. Skikne, H. Anderson, Joseph B. Sipe, 2004, Bone.

Serum transferrin receptor as an index of iron absorption

J. Cook, B. Skikne, S. Dassenko, 1990, British journal of haematology.

Role of gastric acid in food iron absorption.

J. Cook, B. Skikne, S. Lynch, 1981, Gastroenterology.

Serum Transferrin Receptor : A Quantitative Measure of Tissue Iron Deficiency

J. Cook, B. Skikne, C. Flowers, 2003 .

The physiological significance of circulating transferrin receptors.

J. Cook, B. Skikne, R. Baynes, 1994, Advances in experimental medicine and biology.

Erythropoietin, iron, and erythropoiesis.

B. Skikne, C. Brugnara, L. Goodnough, 2000, Blood.

Extended dosing with CC‐486 (oral azacitidine) in patients with myeloid malignancies

K. Kolibaba, B. Skikne, John C. Morris, 2018, American journal of hematology.

CC-486 Maintenance after Stem Cell Transplantation in Patients with Acute Myeloid Leukemia or Myelodysplastic Syndromes

C. Craddock, B. Skikne, R. Champlin, 2018, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

Clinical characteristics and outcomes according to age in lenalidomide-treated patients with RBC transfusion-dependent lower-risk MDS and del(5q)

H. Deeg, P. Greenberg, B. Skikne, 2017, Journal of Hematology & Oncology.

Phase III, Randomized, Placebo-Controlled Trial of CC-486 (Oral Azacitidine) in Patients With Lower-Risk Myelodysplastic Syndromes

P. Vyas, B. Skikne, G. Garcia-Manero, 2021, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Achievement of red blood cell transfusion independence in red blood cell transfusion-dependent patients with lower-risk non-del(5q) myelodysplastic syndromes correlates with serum erythropoietin levels

B. Skikne, P. Fenaux, A. Giagounidis, 2020, Leukemia & lymphoma.

CC-486 (oral azacitidine) in patients with myelodysplastic syndromes with pretreatment thrombocytopenia.

B. Skikne, S. Kambhampati, G. Garcia-Manero, 2018, Leukemia research.

Bone marrow hypocellularity does not affect tolerance or efficacy of azacitidine in patients with higher‐risk myelodysplastic syndromes

G. Mufti, B. Skikne, J. Bennett, 2014, British journal of haematology.

Extended survival and reduced risk of AML progression in erythroid-responsive lenalidomide-treated patients with lower-risk del(5q) MDS

B. Skikne, J. Bennett, S. Nimer, 2013, Leukemia.

Oral Azacitidine Maintenance Therapy for Acute Myeloid Leukemia in First Remission.

H. Döhner, H. Dombret, B. Skikne, 2020, The New England journal of medicine.

Increased release of ferritin and iron by iron-loaded alveolar macrophages in cigarette smokers.

B. Skikne, M. E. Nelson, M. E. Nelson, 1994, American journal of respiratory and critical care medicine.

Serum transferrin receptor is a truncated form of tissue receptor.

J. Cook, B. Skikne, B. Hudson, 1990, The Journal of biological chemistry.

The effect of high ascorbic acid supplementation on body iron stores.

J. Cook, B. Skikne, D. Lipschitz, 1984, Blood.

A serum ferritin assay for prevalence studies of iron deficiency

J. Cook, B. Skikne, J. Beard, 1986, American journal of hematology.

Food iron absorption in idiopathic hemochromatosis.

J. Cook, B. Skikne, S. Lynch, 1989, Blood.

Alveolar macrophage content of isoferritins and transferrin. Comparison of nonsmokers and smokers with and without chronic airflow obstruction.

B. Skikne, L. Wesselius, C. Flowers, 1992, The American review of respiratory disease.

Efficacy and safety of extended dosing schedules of CC-486 (oral azacitidine) in patients with lower-risk myelodysplastic syndromes

B. Skikne, S. Kambhampati, G. Garcia-Manero, 2015, Leukemia.

Effect of enhanced erythropoiesis on iron absorption.

J. Cook, B. Skikne, James D. Cook, 1992, The Journal of laboratory and clinical medicine.

Serum ferritin: a possible model for the assessment of nutrient stores.

J. Cook, B. Skikne, 1982, The American journal of clinical nutrition.

Food Iron Absorption in Idiopathic Hemochromatosis Blood

B. Skikne, 2005 .

Ferritin excretion and iron balance in humans

J. Cook, B. Skikne, P. Whittaker, 1995, British journal of haematology.

Circulating transferrin receptor assay--coming of age.

B. Skikne, 1998, Clinical chemistry.

Occurrence of primary hepatocellular cancer and peliosis hepatis after treatment with androgenic steroids.

S. E. Levin, B. Skikne, T. Bothwell, 1976, South African medical journal = Suid-Afrikaanse tydskrif vir geneeskunde.

Serum transferrin receptor

B. Skikne, 2008, American journal of hematology.

Malignant lymphocytic lymphoma. Demonstration of a serum inhibitor of myelopoiesis and response to combination chemotherapy

B. Skikne, S. Lynch, C. Park, 2006, Cancer.

Is there a plateau in the survival curve after autologous transplantation in patients with intermediate and high-risk acute myeloid leukemia? A 20-year single institution experience.

B. Skikne, J. Lewis, S. Ganguly, 2007, Leukemia research.

Erratum: Extended survival and reduced risk of AML progression in erythroid-responsive lenalidomide-treated patients with lower-risk del(5q) MDS

B. Skikne, J. Bennett, S. Nimer, 2015, Leukemia.

Influence of Karyotype On Overall Survival in Patients with Higher-Risk Myelodysplastic Syndrome Treated with Azacitidine or a Conventional Care Regimen.

A. Hagemeijer, G. Mufti, B. Skikne, 2009 .

A Phase 1, Open-Label, Dose-Escalation Study to Evaluate the Safety, Pharmacokinetics, and Pharmacodynamics of Oral Azacitidine in Patients with Myelodysplastic Syndromes (MDS) or Acute Myelogenous Leukemia (AML).

B. Skikne, G. Garcia-Manero, S. Gore, 2009 .

Oral azacitidine prolongs survival of patients with AML in remission independent of measurable residual disease status.

H. Döhner, F. Thol, H. Dombret, 2022, Blood.

CC-486 (Oral Azacitidine) in Patients with Hematological Malignancies Who Had Received Prior Treatment with Injectable Hypomethylating Agents (HMAs): Results from Phase 1/2 CC-486 Studies

B. Skikne, G. Garcia-Manero, S. Gore, 2016 .

Serum transferrin receptor in the megaloblastic anemia of cobalamin deficiency

B. Skikne, R. Carmel, 1992, European journal of haematology.

Acute myeloid leukemia or myelodysplastic syndrome with chromosome 17 abnormalities and long-term outcomes with or without hematopoietic stem cell transplantation.

A. Godwin, B. Skikne, J. McGuirk, 2020, Leukemia research.

Safety of Lenalidomide (LEN) 10mg in Non-Del(5q) Versus Del(5q) in the Treatment of Patients (Pts) with Lower-Risk Myelodysplastic Syndromes (MDS): Pooled Analysis of Treatment-Emergent Adverse Events (TEAEs)

G. Mufti, B. Skikne, P. Fenaux, 2015 .

116 THE EFFECT OF LENALIDOMIDE ON HEALTH-RELATED QUALITY OF LIFE (HRQOL) IN PATIENTS WITH MDS: RESULTS FROM THE MDS-005 TRIAL

B. Skikne, P. Fenaux, X. Hu, 2015 .

115 MDS-005 STUDY: EFFECT OF BASELINE ENDOGENOUS EPO ON RBC TRANSFUSION INDEPENDENCE (RBC-TI) IN LENALIDOMIDE-TREATED PATIENTS WITH LOW/INTERMEDIATE-1-RISK MDS WITHOUT DEL(5Q)

B. Skikne, P. Fenaux, A. Giagounidis, 2015 .

Pharmacokinetics of different formulations of oral azacitidine (CC‐486) and the effect of food and modified gastric pH on pharmacokinetics in subjects with hematologic malignancies

B. Skikne, M. Savona, B. Scott, 2014, Journal of clinical pharmacology.

Autologous transplantation in patients with relapsed or high-grade follicular lymphoma provides long term disease-free survival and best median duration of response

J. Cook, B. Skikne, S. Ganguly, 2005, Annals of Hematology.

Evaluation of the bioequivalence and food effect on the bioavailability of CC-486 (oral azacitidine) tablets in adult patients with cancer

B. Skikne, M. Abdelrahim, M. Milhem, 2020, Cancer Chemotherapy and Pharmacology.

A randomized, controlled Phase III trial of therapeutic plasma exchange with fresh‐frozen plasma (FFP) prepared with amotosalen and ultraviolet A light compared to untreated FFP in thrombotic thrombocytopenic purpura

J. George, P. Mintz, C. Hillyer, 2006, Transfusion.

Rituximab in the treatment of relapsed thrombotic thrombocytopenic purpura

J. Cook, B. Skikne, S. Ganguly, 2005, Annals of Hematology.

Duodenal iron proteins in idiopathic hemochromatosis.

J. Cook, B. Skikne, S. Lynch, 1989, The Journal of clinical investigation.

An immunoassay for human transferrin.

J. Cook, B. Skikne, A. M. Covell, 1988, The American journal of clinical nutrition.

The QUAZAR AML-001 Maintenance Trial: Results of a Phase III International, Randomized, Double-Blind, Placebo-Controlled Study of CC-486 (Oral Formulation of Azacitidine) in Patients with Acute Myeloid Leukemia (AML) in First Remission

H. Döhner, H. Dombret, B. Skikne, 2019 .

Anaemia, iron deficiency and exercise: extended studies in human subjects.

A. van As, B. Skikne, S. Lynch, 1977, Clinical science and molecular medicine.

Decreased fibrinolytic potential in patients with idiopathic avascular necrosis and transient osteoporosis of the hip

B. Skikne, J. Neff, M. Murphey, 1993, American journal of hematology.

Serum transferrin receptor for the detection of iron deficiency in pregnancy.

J. Cook, B. Skikne, M. Carriaga, 1991, The American journal of clinical nutrition.

16 – The Importance of Animal Products in Human Iron Nutrition

J. Cook, B. Skikne, S. Lynch, 1982 .

Evaluation of Oral Azacitidine Using Extended Treatment Schedules: A Phase I Study

B. Skikne, H. Kantarjian, G. Garcia-Manero, 2010 .

Intestinal regulation of body iron.

J. Cook, B. Skikne, 1987, Blood reviews.

An assessment of dried blood-spot technology for identifying iron deficiency.

J. Cook, B. Skikne, C. Flowers, 1998, Blood.

Cytogenetics and gene mutations influence survival in older patients with acute myeloid leukemia treated with azacitidine or conventional care

L. Bullinger, H. Döhner, P. Vyas, 2018, Leukemia.

Malignant mastocytosis with circulating mast cells

B. Skikne, Karen W Simpson, E. Torrey, 1990, American journal of hematology.

LAG3 Inhibition Decreases AML-Induced Immunosuppression and Improves T Cell-Mediated Killing

A. Godwin, B. Skikne, N. Dunavin, 2019, Blood.

Erythrocyte Catabolism in the Inflammatory Peritoneal Monocyte

B. Skikne, S. Lynch, T. Bothwell, 1978, British journal of haematology.

Iron availability from infant food supplements.

J. Cook, B. Skikne, S. Lynch, 1981, The American journal of clinical nutrition.

Iron Deficiency and the Measurement of Iron Status

J. Cook, B. Skikne, R. Baynes, 1992, Nutrition Research Reviews.

Bovine ferritin iron bioavailability in man

J. Cook, B. Skikne, S. Lynch, 1997, European journal of clinical investigation.

Iron deficiency: the global perspective.

J. Cook, B. Skikne, R. Baynes, 1994, Advances in experimental medicine and biology.

Estimates of iron sufficiency in the US population.

J. Cook, B. Skikne, S. Lynch, 1986, Blood.

Current concepts in iron deficiency anemia

B. Skikne, 1988 .

Serum transferrin receptor: a quantitative measure of tissue iron deficiency.

J. Cook, B. Skikne, C. Flowers, 1990, Blood.

Design of the randomized, Phase III, QUAZAR AML Maintenance trial of CC-486 (oral azacitidine) maintenance therapy in acute myeloid leukemia

M. Voso, B. Skikne, H. Kantarjian, 2016, Future oncology.

Mechanism of thrombocytopenia in chronic hepatitis C as evaluated by the immature platelet fraction

C. Hagedorn, B. Skikne, K. Reid, 2012, International journal of laboratory hematology.

Serum form of the erythropoietin receptor identified by a sequence-specific peptide antibody.

J. Cook, B. Skikne, G. Reddy, 1993, Blood.

Central nervous system involvement in mycosis fungoides. Diagnosis, treatment and literature review

B. Skikne, D. Bodensteiner, 1982, Cancer.

Mechanism of Thrombocytopenia in Hepatitis C as Determined by the Immature Platelet Fraction.

C. Hagedorn, B. Skikne, F. Plapp, 2007 .

Cerebrospinal fluid ferritin levels in screening for meningism.

J. Cook, B. Skikne, D. R. Campbell, 1986, Archives of neurology.

Economic burden associated with acute myeloid leukemia treatment

B. Skikne, B. Smith, A. Zeidan, 2016, Expert review of hematology.

The clinical measurement of serum transferrin receptor.

J. Cook, B. Skikne, C. Flowers, 1989, The Journal of laboratory and clinical medicine.

The quantitative assessment of body iron.

J. Cook, B. Skikne, James D Cook, 2003, Blood.

Prognostic Impact of NPM1 and FLT3 Mutations at Diagnosis and Presence of Measurable Residual Disease (MRD) after Intensive Chemotherapy (IC) for Patients with Acute Myeloid Leukemia (AML) in Remission: Outcomes from the QUAZAR AML-001 Trial of Oral Azacitidine (Oral-AZA) Maintenance

H. Döhner, F. Thol, H. Dombret, 2021, Blood.

Fanconi's anaemia, with special reference to erythrokinetic features.

B. Skikne, W. Bezwoda, S. Lynch, 1978, South African medical journal = Suid-Afrikaanse tydskrif vir geneeskunde.

The enzyme-linked immunosorbent assay: accurate detection of red blood cell antibodies in autoimmune hemolytic anemia.

B. Skikne, P. Brown, F. Plapp, 1983, American journal of clinical pathology.

The effect of food consistency on iron absorption.

J. A. Spicer, J. Cook, B. Skikne, 1983, The American journal of gastroenterology.

Reversible methotrexate associated lymphoproliferative disease evolving into Hodgkin's disease.

B. Skikne, O. Tawfik, H. Lindsley, 2000, The Journal of rheumatology.

Iron Deficiency without Anemia

B. Skikne, G. McLaren, 2019, Nutritional Anemia.

Serum transferrin receptor distinguishes the anemia of chronic disease from iron deficiency anemia.

J. Cook, B. Skikne, R. Baynes, 1992, The Journal of laboratory and clinical medicine.

Pharmacokinetics and Pharmacodynamics with Extended Dosing of CC-486 in Patients with Hematologic Malignancies

B. Skikne, G. Garcia-Manero, S. Gore, 2015, PloS one.

Giant condylomata acuminata: A rare complication of allogeneic bone marrow transplantation

B. Skikne, S. Ganguly, S. Waller, 2006 .

Iron and blood donation.

B. Skikne, S. Lynch, D. Borek, 1984, Clinics in haematology.

Oral Azacitidine (CC-486) for the Treatment of Myeloid Malignancies.

H. Döhner, B. Skikne, G. Garcia-Manero, 2021, Clinical lymphoma, myeloma & leukemia.

Long‐term survival with oral azacitidine for patients with acute myeloid leukemia in first remission after chemotherapy: Updated results from the randomized, placebo‐controlled, phase 3 QUAZAR AML‐001 trial

H. Döhner, H. Dombret, B. Skikne, 2023, American journal of hematology.

Oral azacitidine preserves favorable level of fatigue and health-related quality of life for patients with acute myeloid leukemia in remission: results from the phase III, placebo-controlled QUAZAR AML-001 trial

H. Döhner, H. Dombret, B. Skikne, 2021, Haematologica.

Phase I study of oral azacitidine in myelodysplastic syndromes, chronic myelomonocytic leukemia, and acute myeloid leukemia.

B. Skikne, H. Kantarjian, G. Garcia-Manero, 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Prognostic impact of NPM1 and FLT3 mutations in patients with AML in first remission treated with oral azacitidine

H. Döhner, F. Thol, H. Dombret, 2022, Blood.

Management of adverse events in patients with acute myeloid leukemia in remission receiving oral azacitidine: experience from the phase 3 randomized QUAZAR AML-001 trial

H. Döhner, T. Chevassut, H. Dombret, 2021, Journal of Hematology & Oncology.

CC-486 Prolongs Survival for Patients with Acute Myeloid Leukemia (AML) in Remission after Intensive Chemotherapy (IC) Independent of the Presence of Measurable Residual Disease (MRD) at Study Entry: Results from the QUAZAR AML-001 Maintenance Trial

H. Döhner, F. Thol, H. Dombret, 2020 .

CC-486 Improves Overall Survival (OS) and Relapse-Free Survival (RFS) for Patients with Acute Myeloid Leukemia (AML) in First Remission after Intensive Chemotherapy (IC), Regardless of Amount of Consolidation Received: Results from the Phase III QUAZAR AML-001 Maintenance Trial

H. Döhner, H. Dombret, B. Skikne, 2020 .

CC-486 Reduces Hospitalization and Associated Estimated Costs in Patients with Acute Myeloid Leukemia (AML) in First Remission after Intensive Chemotherapy: Results from the QUAZAR AML-001 Maintenance Trial

B. Skikne, S. Kambhampati, A. Oriol, 2020 .

Long-Term Overall Survival (OS) with Oral Azacitidine (Oral-AZA) in Patients with Acute Myeloid Leukemia (AML) in First Remission after Intensive Chemotherapy (IC): Updated Results from the Phase 3 QUAZAR AML-001 Trial

H. Döhner, H. Dombret, B. Skikne, 2021, Blood.

Circulating transferrin receptors and assessment of iron status

J. Cook, B. Skikne, R. Baynes, 1994 .

Serum form of the erythropoietin receptor identified by a sequence- specific peptide antibody [see comments]

J. Cook, B. Skikne, G. Reddy, 1993 .

Gastrointestinal Events and Management Strategies for Patients with Acute Myeloid Leukemia (AML) in First Remission Receiving CC-486 in the Randomized, Placebo-Controlled, Phase III QUAZAR AML-001 Maintenance Trial

T. Chevassut, H. Dombret, B. Skikne, 2020 .

Final Analysis of the Phase I/II Study of CC-486 (Oral Azacitidine) Maintenance Therapy after Allogeneic Stem Cell Transplantation (Allo-SCT) in Patients with Acute Myeloid Leukemia (AML) or Myelodysplastic Syndromes (MDS)

C. Craddock, B. Skikne, R. Champlin, 2017 .

Oral and parenteral glutamine in bone marrow transplantation: a randomized, double-blind study.

B. Skikne, P. R. Schloerb, 1999, JPEN. Journal of parenteral and enteral nutrition.

A screening test for assessing iron status.

J. Cook, B. Skikne, J. Pintar, 1982, Blood.

Improved differential diagnosis of anemia of chronic disease and iron deficiency anemia: A prospective multicenter evaluation of soluble transferrin receptor and the sTfR/log ferritin index

B. Skikne, K. Punnonen, P. Southwick, 2011, American journal of hematology.

Markers of masked iron deficiency and effectiveness of EPO therapy in chronic renal failure.

B. Skikne, V. Savin, A. Chonko, 1997, American journal of kidney diseases : the official journal of the National Kidney Foundation.

Serum transferrin receptor.

J. Cook, B. Skikne, R. Baynes, 1993, Annual review of medicine.

Pathogenesis and management of iron deficiency anemia: emerging role of celiac disease, helicobacter pylori, and autoimmune gastritis.

B. Skikne, C. Hershko, 2009, Seminars in hematology.

The clinical significance of serum transferrin receptor levels in sickle cell disease

J. Cook, B. Skikne, A. Singhal, 1993, British journal of haematology.

A commercial electrochemical method evaluated for measurement of iron status.

B. Skikne, Barry S. Sklkne, 1987, Clinical chemistry.

Oral azacitidine modulates the bone marrow microenvironment in patients with acute myeloid leukaemia in remission: A subanalysis from the QUAZAR AML‐001 trial

B. Skikne, A. Risueño, T. Prebet, 2023, British journal of haematology.

Effects of erythropoietin therapy on iron absorption in chronic renal failure.

J. Cook, B. Skikne, A. Chonko, 2000, The Journal of laboratory and clinical medicine.

Serum transferrin receptor measurements in hematologic malignancies

B. Skikne, C. Flowers, Dawn Klemow, 1990, American journal of hematology.

The use of the serum transferrin receptor for the assessment of iron status.

J. Cook, B. Skikne, N. Asp, 1996 .

A retrospective analysis of long-term survival in severe aplastic anemia patients treated with allogeneic bone marrow transplantation or immunosuppressive therapy with antithymocyte globulin and cyclosporin A at a single institution.

J. Cook, B. Skikne, R. Ellis, 2002, Military Medicine.

Gastric delivery system for iron supplementation

J. Cook, B. Skikne, W. Schalch, 1990, The Lancet.

Extended Dosing of Oral Azacitidine (CC-486) for 14 and 21 Days Provides More Effective Methylation Reversal Than a 7-Day Schedule

B. Skikne, G. Garcia-Manero, S. Gore, 2012 .

Safety and Efficacy of Oral Azacitidine (CC-486) Administered in Extended Treatment Schedules to Patients with Lower-Risk Myelodysplastic Syndromes

B. Skikne, S. Kambhampati, G. Garcia-Manero, 2012 .

Oral Azacitidine (AZA) Activity in Patients with Acute Myelogenous Leukemia (AML)

B. Skikne, G. Garcia-Manero, S. Gore, 2011 .

Absorption of controlled‐release iron

J. Cook, B. Skikne, David A Lipschitz, 1982, Clinical pharmacology and therapeutics.

Fatal chemotherapy-induced encephalopathy following high-dose therapy for metastatic breast cancer: a case report and review of the literature

B. Skikne, K. Santacruz, P. Johnson, 2003, Bone Marrow Transplantation.

The use of capillary blood for measurements of circulating ferritin.

J. Cook, B. Skikne, P. Pootrakul, 1983, The American journal of clinical nutrition.

Therapy of aplastic anemia with sequential antithymocyte globulin and cyclosporin

B. Skikne, G. Doolittle, M. Amare, 1991, American journal of hematology.

Screening test for iron overload.

J. Cook, B. Skikne, 1987, The American journal of clinical nutrition.

Alveolar macrophages accumulate iron and ferritin after in vivo exposure to iron or tungsten dusts.

B. Skikne, A. O'Brien-Ladner, M. E. Nelson, 1996, Journal of Laboratory and Clinical Medicine.

Giant anal condylomatosis after allogeneic bone marrow transplantation: a rare complication of human papilloma virus infection

B. Skikne, S. Ganguly, S. Waller, 2008, Transplant Infectious Disease.

Serum transferrin receptor

B. Skikne, 2008, American journal of hematology.

Measuring iron-dextran in serum: is it important?

B. Skikne, 1990, Clinical chemistry.

Preliminary Results from a Phase II Study of the Combination of Pevonedistat and Azacitidine in the Treatment of MDS and MDS/MPN after Failure of DNA Methyltransferase Inhibition

G. Ayers, B. Skikne, Sheau-Chiann Chen, 2019, Blood.

CC-486 (Oral Azacitidine) Following Allogeneic Hematopoietic Stem Cell Transplantation (AlloHSCT) in Patients with Myelodysplastic Syndromes (MDS) or Acute Myeloid Leukemia (AML)

C. Craddock, B. Skikne, R. Champlin, 2014 .